{"name":"Universitätsmedizin Mannheim","slug":"universit-tsmedizin-mannheim","ticker":"","exchange":"","domain":"","description":"Universitätsmedizin Mannheim is a leading academic medical center in Germany, focusing on advanced clinical research and patient care. It is part of the University of Heidelberg and collaborates extensively with industry partners to advance medical science and innovation.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Oxaliplatin during radiotherapy","genericName":"Oxaliplatin during radiotherapy","slug":"oxaliplatin-during-radiotherapy","indication":"Locally advanced colorectal cancer (in combination with radiotherapy)","status":"phase_3"}]}],"pipeline":[{"name":"Oxaliplatin during radiotherapy","genericName":"Oxaliplatin during radiotherapy","slug":"oxaliplatin-during-radiotherapy","phase":"phase_3","mechanism":"Oxaliplatin is a platinum-based chemotherapy agent that forms DNA crosslinks to kill cancer cells, and when combined with radiotherapy, enhances radiation-induced cell death through synergistic DNA damage.","indications":["Locally advanced colorectal cancer (in combination with radiotherapy)","Rectal cancer (neoadjuvant chemoradiotherapy)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}